secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001213900-24-002718
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar reports $329M cash; runway into mid-2026
-----------------------------------------------

- Preliminary cash and cash equivalents of $329 million as of December 31, 2023.
- Cash runway expected to fund operations into at least mid-2026.
- Management announced at J.P. Morgan Healthcare Conference on January 10, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390024002718/0001213900-24-002718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390024002718/ea191340-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-002718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer